Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Prototype Developer (U18 Clinical Trial Not Allowed)
ID: 333893Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint MedTech: Prototype Developer program, aimed at supporting the development of human-grade medical device prototypes. This initiative will facilitate projects that encompass product definition and development activities, including needs assessment, product design, prototype development, and bench testing, ultimately preparing for first-in-human testing through subsequent FOAs. The FOA is expected to be published in Summer 2021, with applications due in Fall 2021, and interested applicants can reach out to Michael Wolfson, Ph.D., at Blueprint-MedTech@nih.gov or by phone at 301-451-6987 for further information. There is no cost-sharing or matching requirement for this cooperative agreement, and the opportunity is categorized as discretionary funding for eligible applicants.

    Point(s) of Contact
    Files
    No associated files provided.
    Similar Opportunities
    Forecast for Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the Blueprint MedTech Translator program, aimed at supporting small businesses in the development of innovative medical devices for the nervous and neuromuscular systems. This cooperative agreement will provide non-dilutive funding and additional resources to facilitate the translation of groundbreaking technologies from early-stage development to clinical studies, ultimately accelerating patient access to effective medical devices. Interested applicants should note that while applications are not currently being solicited, they are encouraged to begin forming collaborations and developing projects in anticipation of the NOFO, with an estimated synopsis posting date of July 21, 2025, and a closing date of October 20, 2025. For further inquiries, potential applicants can contact Nicholas Langhals, PhD, at Blueprint-MedTech@nih.gov or by phone at 301-435-0090.
    Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)" aimed at supporting innovative research in the development of therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. This cooperative agreement program encourages investigators to conduct translational activities and clinical feasibility studies, with a focus on advancing medical device technology through collaboration with NIH resources for design, testing, and regulatory support. The initiative is particularly significant as it seeks to accelerate the clinical introduction of medical technologies, ultimately improving patient outcomes while adhering to best practices in research and development. Interested applicants, including various eligible institutions and organizations, must submit their proposals by January 28, 2028, and can find more information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition – Medical Device Prototype Optimization" (RFA-HL-26-020) aimed at supporting early-stage translational research for the optimization of prototypes related to heart, lung, blood, and sleep (HLBS) diseases. This initiative seeks to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates, encouraging significant improvements over existing solutions through strong biological rationale and preliminary data. The total anticipated funding is approximately $4.466 million per fiscal year from FY 2026 to FY 2028, with applications due by 5 PM local time on specified dates, and a maximum project duration of two years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity titled "Catalyze Product Definition," aimed at supporting the development of medical device prototypes, diagnostic targets, and related research tools for heart, lung, blood, and sleep (HLBS) diseases. This initiative adopts a phased approach (R61/R33) to assist early-stage projects, focusing on preliminary prototype testing in the R61 phase and advancing to extensive development activities in the R33 phase, with a requirement for applicants to demonstrate novelty and a strong biological rationale supported by preliminary data. The program anticipates funding approximately $4.4 million annually from FY 2026 to FY 2028, with up to 24 awards available, and requires applicants to engage with an Accelerator Partner to enhance commercialization expertise. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline of December 23, 2027.
    Notice of Intent to Publish a Funding Opportunity Announcement: Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at soliciting applications for research focused on developing biomedical technologies that address health disparities. This initiative seeks to support projects that create effective, affordable, and socially acceptable technologies to improve healthcare access and outcomes for underserved populations. The estimated total program funding for this opportunity is $1,200,000, with an expected two awards to be made, and the application process is anticipated to open in late 2025. Interested applicants can reach out to Nichole Daringer at nichole.daringer@nih.gov or call 301-451-4774 for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed) aimed at fostering collaborations between academic and industrial organizations to develop innovative biomedical solutions. This initiative encourages the establishment of robust engineering solutions to address significant biomedical challenges, requiring applicants to form strategic alliances and outline a detailed plan with specific milestones to achieve results within 5-10 years. The anticipated funding opportunity announcement is expected to be published in February 2022, with applications due by May 2022, and the estimated award date is set for April 1, 2023. For further inquiries, interested parties can contact Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov.
    Small Business Translator: MedTech and Digital Health Technologies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Business Translator: MedTech and Digital Health Technologies" aimed at encouraging small business concerns (SBCs) to engage in translational activities and clinical studies for the development of innovative health technologies. This cooperative agreement program seeks to advance technologies that prevent, monitor, diagnose, and treat various disorders, with a focus on devices such as wearables, digital health tools, and imaging-based biomarkers, among others. Participants will receive funding for activities conducted in their laboratories and may also collaborate with consultants for specialized support, with key deadlines including an estimated synopsis close date of October 20, 2025, and an estimated award date of July 1, 2026. For further inquiries, interested applicants can contact Nicholas Langhals, PhD, at Blueprint-MedTech@nih.gov or by phone at 301-435-0090.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing innovative technologies in biomedical research. This initiative seeks applications that propose high-risk, high-reward projects focused on technology development without existing proof of concept, specifically excluding clinical trials. The funding amount is capped at $275,000 in direct costs over two years, with a maximum of $200,000 available in any single year. Interested applicants, including higher education institutions and nonprofit organizations, must adhere to submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is January 7, 2028.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), aimed at advancing biologic-based drug discovery and development for disorders of the nervous system. This initiative seeks applications from researchers focused on developing a variety of biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, specifically targeting nervous system and neuromuscular disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the UG3/UH3 activity code. Interested applicants should prepare for collaboration opportunities, as the estimated award date is set for December 1, 2025.